Format

Send to

Choose Destination
Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Author information

1
From the Sahlgrenska Translational Melanoma Group, Institute of Clinical Science, Departments of Surgery and Oncology, Sahlgrenska Cancer Center at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, 405 30, Sweden.
2
Center for Cancer Immune Therapy, Department of Hematology and Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, DK-2730, Denmark.
3
Internal Medicine III, Technische Universität München, Munich, 81675, Germany.
4
German Cancer Consortium/Deutsches Krebsforschungszentrum, Heidelberg, 69120, Germany.
5
From the Sahlgrenska Translational Melanoma Group, Institute of Clinical Science, Departments of Surgery and Oncology, Sahlgrenska Cancer Center at University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, 405 30, Sweden. jonas.a.nilsson@surgery.gu.se.

Abstract

Immune checkpoint inhibitors and adoptive cell transfer (ACT) of autologous tumor-infiltrating T cells have shown durable responses in patients with melanoma. To study ACT and immunotherapies in a humanized model, we have developed PDXv2.0 - a melanoma PDX model where tumor cells and tumor-infiltrating T cells from the same patient are transplanted sequentially in non-obese diabetic/severe combined immune-deficient/common gamma chain (NOG/NSG) knockout mouse. Key to T-cell survival/effect in this model is the continuous presence of interleukin-2 (IL-2). Tumors that grow in PDXv2.0 are eradicated if the autologous tumor cells and T cells come from a patient that exhibited an objective response to ACT in the clinic. However, T cells from patients that are non-responders to ACT cannot kill tumor cells in PDXv2.0. Taken together, PDXv2.0 provides the potential framework to further model genetically diverse human cancers for assessing the efficacy of immunotherapies as well as combination therapies.Combining different types of immune therapies might benefit certain patients. Here, the authors develop an autologous immune-humanized melanoma mouse model that allows the preclinical assessment of cancer cell-T cell interactions from each individual patient and the benefits of immunotherapies combinations.

PMID:
28955032
PMCID:
PMC5617838
DOI:
10.1038/s41467-017-00786-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center